Safety and Efficacy of Lapatinib Plus Trastuzumab or Lapatinib Plus Capecitabine in Metastatic Breast Cancer (THOR)

This study has been withdrawn prior to enrollment.
(Due to missing patient recruitment, the financial support was stopped.)
Sponsor:
Collaborator:
OnkoDataMed GmbH
Information provided by (Responsible Party):
Berufsverband Niedergelassener Gynäkologischer Onkologen in Deutschland e.V.
ClinicalTrials.gov Identifier:
NCT01985893
First received: November 10, 2013
Last updated: January 13, 2016
Last verified: January 2016
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Study Completion Date: March 2015
  Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)